
<DOC>
<DOCNO>WT01-B23-4</DOCNO>
<DOCOLDNO>IA087-000627-B014-40</DOCOLDNO>
<DOCHDR>
http://206.61.184.43:80/schaffer/hemp/medical/ctp2.htm 206.61.184.43 19970122050945 text/html 64051
HTTP/1.0 200 OK
Date: Wednesday, 22-Jan-97 05:09:34 GMT
Server: WebSitePro/1.1f (S/N wpo-0deb)
Allow-ranges: bytes
Content-type: text/html
Last-modified: Saturday, 28-Dec-96 06:01:13 GMT
Content-length: 63833
</DOCHDR>
<html>

<head>
<title>Cannabis Therapeutic Program DETAILED PROTOCOL RESULTS </title>
<meta name="GENERATOR"
content="Internet Assistant for Microsoft Word 2.0z Beta">
</head>

<body>

<p> </p>
</body>

<body bgcolor="#ffffff">

<p><img src="../../graphics/blueline.gif"> </p>

<p> <b><font size="2">California Research Advisory Panel</font></b>
</p>

<h1>Cannabis Therapeutic Program</h1>

<p> <img src="../../graphics/blueline.gif"><br>
</p>

<p> <font size="1">DETAILED PROTOCOL RESULTS <br>
</font> </p>

<p> <font size="2">Interpretations of efficacy of THC are limited
by the fact that in this study no control group could be
established for comparison with the treatment group. Thus, some
of the findings are more anecdotal than quantitative. However,
the following results are clear, reasonable and documented. <br>
<br>
</font> </p>

<p> <font size="2">Number of Patients Treated <br>
</font> </p>

<p> <font size="2">A total of 2,475 patients were treated with
THC or smoked marijuana under one or more of the following
protocols: <br>
</font> </p>

<p> <font size="2">Smoked Marijuana Protocols 119<br>
</font> </p>

<p> <font size="2">The compassionate access</font> </p>

<p> <font size="2">THC protocols 2400<br>
</font> </p>

<p> <font size="2">Dexamethasone Protocol 4 <br>
</font> </p>

<p> <font size="2">Transderm-V Protocol 65<br>
</font> </p>

<p> <font size="2">Delta-8-THC Protocol 10<br>
</font> </p>

<p> <font size="2">Pilot Protocol (protocol</font> </p>

<p> <font size="2">exceptions) 19<br>
</font> </p>

<p> <font size="2">Glaucoma Protocol 9<br>
<br>
</font> </p>

<p> <font size="2">Because of the protocol revisions previously
described, data had to be tabulated separately for each of the
several compassionate access THC protocols (subjects who received
THC for nausea and vomiting associated with cancer chemotherapy):<br>
<br>
a) <u>Initial Trial</u> 856 patients enrolled in the initial
Protocols I, II, and III between November 1980 and April 1982,
and followed until October 1982. <br>
b) <u>Cumulative Dose Protocol </u>365 patients enrolled in the
Cumulative Dose Protocol.<br>
</font> </p>

<p> <font size="2">c) <u>Combination Antiemetic Protocol</u> 657
patients enrolled in the Combination Antiemetic Protocol, whose
treatment report forms were returned to RAP after January 1,
1984.<br>
</font> </p>

<p> <font size="2">Initial Trial<br>
<u>Summary</u>. These first results reflect data from an open
multisite cooperative study conducted to evaluate
delta-9-tetrahydrocannabinol (THC) in patients receiving
anticancer therapy who previously had been treated with other
antiemetics.<br>
</font> </p>

<p> <font size="2">Oral THC was found to be effective in reducing
nausea, vomiting and anorexia.</font> </p>

<p> <font size="2">Effectiveness was related to chemotherapeutic
regimen, generally being most effective with the less emetogenic
agents. <br>
Side effects were common. Serious adverse reactions were reported
by physicians for nine patients, but none of these were life
threatening. There was no significant difference between the
effectiveness of the 5mg/m2 and 7.5mg/m2 doses, but 5mg/M2 was
associated with fewer side effects, a lower dropout rate due to
side effects and a greater number of patients continuing THC
treatment. Thus, 5mg/m2 is the preferred dose. The incidence of
clinically serious adverse reactions to oral THC was less than
one percent.<br>
</font> </p>

<p> <u><font size="2">Patient and Investigator</font></u> </p>

<p> <u><font size="2">Demographics</font></u><font size="2"> Of
about 300 board certified and eligible oncologists, one hundred
seventy-nine enrolled 856 patients, of which 706 were evaluable.
Patients were enrolled between November 1980 and April 1982, and
were followed until October 1982, at which time a final
disposition was obtained on each patient. A total of 150 patients
were excluded from analysis due to incomplete report forms,
enrollment at dosages other than 5mg/m2 or 7.5mg/m and enrollment
by 26 investigators who did not adhere to the protocol.<br>
</font> </p>

<p> <font size="2">To avoid bias caused by selective
dropping-out, only results from the first treatment episode are
analyze in this report, although over half the patients received
THC in two or more discrete episodes for a total of 1622
treatments in this initial trial. Results of second and
subsequent episodes are statistically more favorable since
patients with disturbing side effects and those with good results
self-select for continuation or termination. <br>
</font> </p>

<p> <font size="2">Sixty percent entered the study at a THC dose
of 7.5m 2g/m2 ; 40% entered at the 5mg/ml dose level. Sixty-two
percent of the patients were female. The median age for women was
49, and for men was 38. Sixty-four percent of the patients had
breast, lung. ovarian, or hematopoietic neoplasms. Seventyseven
percent of the patients were able to carry on <u>normal</u>
activities despite their disease (Karnofsky <u>performance</u>
status of 80 or more). </font> </p>

<p> <font size="2">Ninety-nine percent of patients had failed to
benefit significantly from other antiemetics, which were
phenothiazines (87Z), butyrophenones (6%), metoclopramide (6%),
and others (3%). A wide variety of chemotherapeutic agents were
used, usually in combinations. The number of patients per
participating physician varied widely: 69 physicians or 41% of
them had one or two patients while 25 physicians (15%) had 10 or
more patients in the program (Table B).<br>
</font> </p>

<p> <font size="2">Proportionately, among men there were more
young persons than among women: 30% of the men compared with only
132 of the women were below 30 years. 44% of the men and 611 of
the women were in the age group 30-59 years. The age groups above
60 years were equally represented among men and women (26%)
(Table C). <br>
</font> </p>

<p> <font size="2">The tumor sites most commonly represented
among the patients in the THC program were, for women, carcinoma
of the breast (38%) and cancer of the ovary or uterus (21%). The
most common primary tumor sites among the men were Hodgkin's
lymphoma (18%) and lung carcinoma (18%) (Table D). It should be
emphasized, however, that the distribution of primary organ
locations is not representative of the prevalence by site in the
general population. <br>
</font> </p>

<p> <center><font size="2">Table B<br>
</font></center> </p>

<p> <font size="2">Frequency Distribution of 167 Physicians<br>
</font> </p>

<p> <font size="2">by Number of Patients Treated with THC
Capsules</font> </p>

<p> <font size="2">------------------------------------------------
<br>
</font> </p>

<p> <font size="2">Number Frequency Number Frequency</font> </p>

<p> <font size="2">of of of of</font> </p>

<p> <font size="2">Patients Physicians Patients Physicians</font>
</p>

<p> <font size="2">-------- ---------- -------- ----------</font>
</p>

<p> <font size="2">1 33 13 2</font> </p>

<p> <font size="2">2 36 14 3</font> </p>

<p> <font size="2">3 18 15 2</font> </p>

<p> <font size="2">4 18</font> </p>

<p> <font size="2">5 12 15 1</font> </p>

<p> <font size="2">6 5 1</font> </p>

<p> <font size="2">7 8 21 1</font> </p>

<p> <font size="2">8 5</font> </p>

<p> <font size="2">9 5 28 1</font> </p>

<p> <font size="2">10 6</font> </p>

<p> <font size="2">11 3 29 1</font> </p>

<p> <font size="2">12 5<br>
</font> </p>

<p> <font size="2">---------------------------------------------------------
<br>
</font> </p>

<p> <font size="2">167 physicians treated 809 patients with THC
capsules. <br>
<br>
<br>
<br>
</font> </p>

<p> <center><font size="2">Table C<br>
</font></center> </p>

<p> <center><font size="2">Characteristics of Study<br>
</font></center> </p>

<p> <center><font size="2">Population of the Initial Trial</font></center>
</p>

<p> <center><font size="2">------------------------------- <br>
</font></center> </p>

<p> <font size="2">Male Female<br>
</font> </p>

<p> <font size="2">No. Percent No. Percent</font> </p>

<p> <font size="2">--- ------- --- ------- <br>
</font> </p>

<p> <font size="2">Sex: 306 37.92 501 62.08 <br>
</font> </p>

<p> <font size="2">Age Distribution:<br>
</font> </p>

<p> <font size="2">19 yrs or less 23 7.52 29 5.79</font> </p>

<p> <font size="2">20 - 29 yrs 67 21.90 36 7.19</font> </p>

<p> <font size="2">30 - 39 yrs 57 18.63 81 16.17</font> </p>

<p> <font size="2">40 - 49 yrs 30 9.80 99 19.76</font> </p>

<p> <font size="2">50 - 59 yrs 44 14.38 125 24.95</font> </p>

<p> <font size="2">60 - 69 yrs 56 18.30 96 19.16</font> </p>

<p> <font size="2">70 yrs or more 23 7.52 32 6.39</font> </p>

<p> <font size="2">Unknown 6 1.96 3 0.60<br>
</font> </p>

<p> <font size="2">--------------------------------------------------------
<br>
</font> </p>

<p> <font size="2">Base: 890 patients receiving capsules.<br>
</font> </p>

<p> <font size="2">Exclusions: 2 patients with sex unreported.<br>
</font> </p>

<p> <center><font size="2">Table D<br>
</font></center> </p>

<p> <font size="2">Distribution of Primary Tumor Site by Sex</font>
</p>

<p> <font size="2">----------------------------------------- <br>
<br>
</font> </p>

<p> <font size="2">Primary Tumor Site Males Females<br>
</font> </p>

<p> <i><font size="2">No.</font></i><font size="2"> Percent No.
Percent <br>
</font> </p>

<p> <font size="2">Lip. Oral Cavity &amp; Pharynx 7 2.3 5 1.0<br>
</font> </p>

<p> <font size="2">Digestive Organs &amp;</font> </p>

<p> <font size="2">Peritoneum 36 12.0 21 4.2</font> </p>

<p> <font size="2">Examples:</font> </p>

<p> <font size="2">Stomach 6 2.0 1 0.2</font> </p>

<p> <font size="2">Colon, Caecum, 11 3.7 10 2.0</font> </p>

<p> <font size="2">Pancreas 6 2.0 4 0.8<br>
</font> </p>

<p> <font size="2">Respiratorv &amp; Intra-</font> </p>

<p> <font size="2">thoracic Organs 68 22.6 49 9.8</font> </p>

<p> <font size="2">Examples:</font> </p>

<p> <font size="2">Lung-Trachea 53 17.6 40 8.0 <br>
</font> </p>

<p> <font size="2">Thymus, Heart &amp;</font> </p>

<p> <font size="2">Mediastinum 12 4.0 6 1.2 <br>
</font> </p>

<p> <font size="2">Bone. Connective-Tissue,</font> </p>

<p> <font size="1">Skin </font><font size="2">&amp; breast 39
13.0 216 43.3</font> </p>

<p> <font size="2">Examples:</font> </p>

<p> <font size="2">Bone &amp; Articular</font> </p>

<p> <font size="2">Cartilage 20 6.6 10 2.0<br>
</font> </p>

<p> <font size="2">Connective &amp; Other</font> </p>

<p> <font size="2">Soft Tissue 10 3.3 11 2.2 <br>
</font> </p>

<p> <font size="2">Female Breast 191 38.3 <br>
</font> </p>

<p> <font size="2">Genitourinarv Organs 41 .13.6 124 .24.8</font>
</p>

<p> <font size="2">Examples:</font> </p>

<p> <font size="2">Uterus 6 1.2<br>
</font> </p>

<p> <font size="2">Ovary &amp; Other Uterine</font> </p>

<p> <font size="2">Adnexa 106 21.2<br>
</font> </p>

<p> <font size="2">Prostate 10 3.3</font> </p>

<p> <font size="2">Testis 24 8.0<br>
</font> </p>

<p> <font size="2">Lymphatic &amp; heamatopoeitic</font> </p>

<p> <b><font size="1">Tissue</font></b><font size="1"> </font><font
size="2">73 24.3 46 9.2</font> </p>

<p> <font size="2">Examples:</font> </p>

<p> <font size="2">Hodgkin's Disease 55 18.3 30 6.0</font> </p>

<p> <font size="2">Myeloid Leukemia 9 3.0 8 1.6<br>
</font> </p>

<p> <font size="2">Other unspecified sites 37 12.3 38 7.6<br>
</font> </p>

<p> <font size="2">-----------------------------------------------------------------</font>
</p>

<p> <font size="2">499 100.0<br>
</font> </p>

<p> <font size="2">Total (n-800)<br>
</font> </p>

<p> <font size="2">301 100.0<br>
</font> </p>

<p> <u><font size="2">Study design</font></u><font size="2">. The
California statute that established the cannabis program includes
the objective of providing 'compassionate access' to marijuana
for cancer patients receiving chemotherapy and radiotherapy.
Strict experimental control measures were thereby precluded.
Patients served as their own controls. however, through
comparison with previous antiemetic trials.<br>
</font> </p>

<p> <u><font size="2">Drug dose and schedule</font></u><font
size="2">. The drug was supplied by the National Cancer Institute
as soft gelatin capsules containing 2.5, 5 and 10mg
delta-9tetrahydrocannabinol dissolved in sesame oil. Based on
dosage, two cohorts of patients participated in this initial
study. Patients in the first cohort received 7.5mg THC/m2 every
four hours while awake starting six hours prior to anticancer
therapy, and continuing for 24 to 48 hours after its completion.
If severe side effects occurred, the physician had the option to
either delay, omit, or reduce the next dose, or discontinue THC
treatment. Preliminary results from the 7.5mg/m2 dose regimen
indicated that a lower starting dose of THC might be better
tolerated. Thus, patients in the second cohort were those given
5mg THC/m2 in the same manner. <br>
</font> </p>

<p> <u><font size="2">Efficacy</font></u><font size="2">. In 482
patients, the identical anticancer treatment was used with the
THC treatment episode and with the prior treatment episode,
allowing comparison of the efficacy of THC to a standard
antiemetic. As illustrated in Table E, nausea and vomiting were
better controlled by THC than by previous antiemetics in 752 and
731 of patients respectively. Fifty-five percent of patients
reported improved food intake. Although some nausea and vomiting
occurred in most patients during the THC trial, as shown in
Tables F and G, nausea was absent in 17% and mild in 38% of the
patients. Vomiting was absent in 30% of the population. and in
another 33% occurred an average of less than four times daily. As
illustrated in Table B. 62% of patients rated THC moderately to
very effective. Physicians' effectiveness ratings for THC used in
conjunction with various chemotherapy agents are summarized in
Table I. Depending on the anticancer agent used, THC was
effective in anywhere from 38% to 662 of the patients. No
statistically significant associations were found between
effectiveness and age, sex or primary tumor site.<br>
</font> </p>

<p> <u><font size="2">Effectiveness and Chemotherapeutic Drugs</font></u><font
size="2">. Because of the size of this statewide cooperative
study, assessment of effectiveness of THC was possible with
specific chemotherapeutic regimens. As rated by physicians THC
was most effective with chemotherapy regimens known as CMF5*,
FAC**, and AC***. Physicians rated THC as moderately or very
effective in 82 percent of the treatment episodes involving CMF,
76 percent of those involving FAC, and 75 percent of those
involving AC. THC was least effective with DTA**** and</font> </p>

<p> <font size="2">CISCA*****, yet over 40 percent of these
patients benefitted significantly.<br>
<br>
</font><font size="1">5. CMF Is Cyclophosphamide. nethotrexate
&amp; 5-FU<br>
FAC is 5-FU. Adriamycin &amp; cyclophosphamide</font> </p>

<p> <font size="1">*** AC Is Adriamycin &amp; cyclophosphaside<br>
*** DTA Is Decarbazine &amp; Adriamycin</font> </p>

<p> <font size="1">:**** CISCA in Cisplatin, cyclophosphamide
&amp; Adriemycin<br>
</font> </p>

<p> <center><font size="2">Table E<br>
</font></center> </p>

<p> <center><font size="2">Patient's Assessment of Symptoms:<br>
</font></center> </p>

<p> <center><font size="2">THC Compared to Previous Antiemetic*</font></center>
</p>

<p> <font size="2">----------------------------------- <br>
<br>
<br>
</font> </p>

<p> <font size="2">Severity of Nausea Vomiting Anorexia</font> </p>

<p> <font size="2">Symptoms No. No. % No.</font> </p>

<p> <font size="2">----------- ---------- -----------
------------<br>
</font> </p>

<p> <font size="2">Less with THC 363 75 350 73 264 55</font> </p>

<p> <font size="2">Same 78 16 61 13 119 25</font> </p>

<p> <font size="2">Greater with THC 41 9 67 14 93 20</font> </p>

<p> <font size="2">Total 482 100 478 100 476 100<br>
</font> </p>

<p> <font size="2">----------------------------------------------------------------Only
includes patients whose anticancer treatment was unchanged.<br>
<br>
<br>
<br>
<br>
<br>
</font> </p>

<p> <center><font size="2">Table F<br>
</font></center> </p>

<p> <center><font size="2">Nausea during THC Protected</font></center>
</p>

<p> <center><font size="2">Anticancer Treatment</font></center> </p>

<p> <center><font size="2">--------------------------- <br>
<br>
</font></center> </p>

<p> <font size="2">Nausea Rating Number of Patients Percent</font>
</p>

<p> <font size="2">------------- ------------------ -------<br>
</font> </p>

<p> <font size="2">None 112 17<br>
</font> </p>

<p> <font size="2">Mild 248 38<br>
</font> </p>

<p> <font size="2">Moderate 166 25<br>
</font> </p>

<p> <font size="2">Severe 130 20<br>
</font> </p>

<p> <font size="2">Total 656 100<br>
</font> </p>

<p> <font size="2">----------------------------------------------
<br>
</font> </p>

<p> <center><b><font size="2">Table </font></b><font size="2">G <br>
</font></center> </p>

<p> <center><font size="2">Vomiting during THC Protected</font></center>
</p>

<p> <center><font size="2">Anticancer Treatment <br>
</font></center> </p>

<p> <center><font size="2">----------------------------- <br>
<br>
</font></center> </p>

<p> <font size="2">Amount of Vomiting Number of Patients Percent</font>
</p>

<p> <font size="2">------------------ ------------------ -------<br>
</font> </p>

<p> <font size="2">None 197 30<br>
</font> </p>

<p> <font size="2">1-3 times 218 33<br>
</font> </p>

<p> <font size="2">4-6 times 83 13<br>
</font> </p>

<p> <font size="2">7 or more times 158 24<br>
</font> </p>

<p> <font size="2">Total 656 100<br>
</font> </p>

<p> <font size="2">-----------------------------------------------------
<br>
<br>
<br>
<br>
<br>
<br>
<br>
<br>
</font> </p>

<p> <center><font size="2">Table H<br>
</font></center> </p>

<p> <center><font size="2">Patient Overall Assessment <br>
</font></center> </p>

<p> <center><font size="2">of THC Effectiveness</font></center> </p>

<p> <center><font size="2">-------------------------- <br>
<br>
<br>
</font></center> </p>

<p> <font size="2">Degree of Effectiveness Number of Patients
Percent</font> </p>

<p> <font size="2">----------------------- ------------------
------- <br>
</font> </p>

<p> <font size="2">None 152 24<br>
</font> </p>

<p> <font size="2">Slight 92 14<br>
</font> </p>

<p> <font size="2">Moderate 196 30<br>
</font> </p>

<p> <font size="2">Very 203 32<br>
</font> </p>

<p> <font size="2">Total 643 100<br>
</font> </p>

<p> <center><font size="2">Table I<br>
<br>
</font></center> </p>

<p> <center><font size="2">Physician's Effectiveness Rating of</font></center>
</p>

<p> <center><font size="2">THC by Chemotherapy Regimen</font></center>
</p>

<p> <center><font size="2">----------------------------------- <br>
<br>
</font></center> </p>

<p> <font size="2">Chemotherapy Regimen Total Number Moderate or
Very</font> </p>

<p> <font size="2">of Patients Effective Rating</font> </p>

<p> <font size="2">-------------------- ------------
---------------- <br>
</font> </p>

<p> <font size="2">No.<br>
</font> </p>

<p> <font size="2">5 Fluorouracil, Adriamycin</font> </p>

<p> <font size="2">and cyclophosphamide 32 21 66<br>
<br>
</font> </p>

<p> <font size="2">Cyclophosphamide, metho-</font> </p>

<p> <font size="2">trexate and 5 fluorouracil 56 37 66<br>
<br>
</font> </p>

<p> <font size="2">Adriamycin and cyclophosphamide 90 57 63<br>
<br>
</font> </p>

<p> <font size="2">Cyclophosphamide, Adriamycin,</font> </p>

<p> <font size="2">vincristine and prednisone 51 28 55<br>
<br>
</font> </p>

<p> <font size="2">Cisplatin, cyclophosphamide</font> </p>

<p> <font size="2">and Adriamycin 50 20 40<br>
<br>
</font> </p>

<p> <font size="2">Dacarbazine and Adriamycin 34 13 38<br>
</font> </p>

<p> <u><font size="1">Safety</font></u><font size="1">.
Physicians were required to make a separate report of any
clinically serious adverse reaction, defined as a reaction while
taking THC that required the use of drugs or hospitalization of
the patient. During the course of this trial, five clinically
serious adverse reactions were reported among the first 856
patients treated with THC. There were two instances of severe
psychological distress (anxiety), and one case each of myoclonic
jerking, postural hypotension, and grand mal seizure.
Complicating factors, for example, brain metastasis associated
with the seizure, were present in three cases. All patients with
serious adverse reactions had the drug immediately discontinued
and recovered fully with no sequelae. Generally, no other drug
treatment was needed.<br>
</font> </p>

<p> <u><font size="1">Side Effects</font></u><font size="1">.
Side effects were common: even at the lower dose, about 80% of
patients had at least one side effect, and in 26% of those
patients, at least one side effect was considered severe. The
severe side effects with an incidence of 5% or greater were all
central nervous system effects. A significant difference between
the sexes was observed: nine percent of women reported severe
anxiety as compared to 4% of men (p=.025).<br>
</font> </p>

<p> <u><font size="1">Influence of Dose</font></u><font size="1">
Level. The THC dose level was found to influence the frequency of
side effects and drug-related reasons for dropping out of the
study, but did not influence drug effectiveness. <br>
</font> </p>

<p> <font size="1">The frequency and nature of various side
effects rated as moderate and severe for both THC </font><font
size="2">dose levels are listed in Table J. Dose level influenced
which side effects were reported most frequently as severe. At
7.5mg/m2, the two most common severe side effects were confusion
and anxiety. At 5mg/m2, these were sedation and confusion.
Patients receiving 5mg/m2 reported an average of 3.3 moderate and
severe side effects, compared with 4.4 per patient receiving
7.5mg/m2. Side effects were almost always less severe when the
lower dose of THC was used, and this difference was significant
for seven of the 13 categories of side effects. <br>
</font> </p>

<p> <font size="2">While there was no statistically significant
difference between the high overall dropout rates associated with
either dose level, patients receiving the higher dose were more
likely to drop out because of side effects than were those on the
lower dose. Forty seven percent of the patients receiving 5mg/m2
and 492 receiving 7.5mg/M2 dropped out of the study before
receiving a second THC treatment. Approximately 20% of patients
in both groups dropped out for non-drug reasons (e.g., moved,
died, completed chemotherapy). 2 Of the patients who received
5mg/m 682 dropped out because THC was ineffective, and 32%dropped
out because THC produced side effects judged by the patient to be
intolerable. In contrast, in the 7.5mg/m2 group, only 521 dropped
out due to drug ineffectiveness, and 48% dropped out due to
intolerable side effects, a significant difference between doses
(P&lt;.05). There was no difference in the overall drop-out rate
between the two dosage groups.<br>
</font> </p>

<p> <u><font size="2">Safety</font></u><font size="2">.
Physicians were required to make a separate report of any
clinically serious adverse reaction, defined as a reaction while
taking THC that required the use of drugs or hospitalization of
the patient. During the course of this trial, five clinically
serious adverse reactions were reported among the first 856
patients treated with THC. There were two instances of severe
psychological distress (anxiety), and one case each of myoclonic
jerking, postural hypotension, and grand mal seizure.
Complicating factors, for example, brain metastasis associated
with the seizure, were present in three cases. All patients with
serious adverse reactions had the drug immediately discontinued
and recovered fully with no sequelae. Generally, no other drug
treatment was needed.<br>
</font> </p>

<p> <u><font size="2">Side Effects</font></u><font size="2">.
Side effects were common: even at the lower dose, about 80% of
patients had at least one side effect, and in 262 of those
patients, at least one side effect was considered severe. The
severe side effects with an incidence of 5% or greater were all
central nervous system effects. A significant difference between
the sexes was observed: nine percent of women reported severe
anxiety as compared to 42 of men (p=.025).<br>
</font> </p>

<p> <u><font size="2">Influence of Dose</font></u><font size="2">
Level. The THC dose level was found to influence the frequency of
side effects and drug-related reasons for dropping out of the
study, but did not influence drug effectiveness. <br>
</font> </p>

<p> <font size="2">The frequency and nature of various side
effects rated as moderate and severe for both THC dose levels are
listed in Table J. Dose level influenced which side effects were
reported most frequently as severe. At 7.5mg/m2, the two most
common severe side effects were confusion and anxiety. At 5mg/m2,
these were sedation and confusion. Patients receiving 5mg/m2
reported an average of 3.3 moderate and severe side effects,
compared with 4.4 per patient receiving 7.5mg/m2. Side effects
were almost always less severe when the lower dose of THC was
used, and this difference was significant for seven of the 13
categories of side effects. <br>
</font> </p>

<p> <font size="2">While there was no statistically significant
difference between the high overall dropout rates associated with
either dose level, patients receiving the higher dose were more
likely to drop out because of side effects than were those on the
lower dose. Fortyseven percent of the patients receiving 5mg/m2
and 492 receiving 7.5mg/M2 dropped out of the study before
receiving a second THC treatment. Approximately 20% of patients
in both groups dropped out for non-drug reasons (e.g., moved,
died, completed chemotherapy). Of the patients who received
5mg/M2, 681 dropped out because THC was ineffective, and 32Z
dropped out because THC produced side effects judged by the
patient to be intolerable. In contrast, in the 7.5mg/m2 group,
only 52% dropped out due to drug ineffectiveness, and 482 dropped
out due to intolerable side effects, a significant difference
between doses (P&lt;.05). There was no difference in the overall
drop-out rate between the two dosage groups.<br>
</font> </p>

<p> <center><font size="2">Table J<br>
</font></center> </p>

<p> <center><font size="2">Comparison of the Incidence of Side<br>
</font></center> </p>

<p> <center><font size="2">Effects with 5/mg/m2 vs. 7.5mg/m2 THC</font></center>
</p>

<p> <center><font size="2">------------------------------------- <br>
<br>
</font></center> </p>

<p> <font size="2">Side Effect</font> </p>

<p> <font size="2">(Incidence as Moderate Severe</font> </p>

<p> <font size="2">percentage)</font> </p>

<p> <font size="2">7.5mg/m2 5mg/m2 7.5mg/m2 5mg/m2</font> </p>

<p> <font size="2">------------- ------ -------- ------<br>
</font> </p>

<p> <font size="2">Dry mouth** 46.5 35.4 3.9 3.2<br>
</font> </p>

<p> <font size="2">Tachycardia 12.0 10.9 2.0 1.1<br>
</font> </p>

<p> <font size="2">Ataxia** 21.9 18.3 5.4 1.1 <br>
</font> </p>

<p> <font size="2">Dizziness 41.7 27.1 8.7 4.6 <br>
</font> </p>

<p> <font size="2">Orthostatic</font> </p>

<p> <font size="2">hypotension 16.8 14.1 3.0 2.5.<br>
</font> </p>

<p> <font size="2">Anxiety** 22.3 14.4 3.8 <br>
</font> </p>

<p> <font size="2">Sedation* 56.9 47.7 6.8 7.0 <br>
</font> </p>

<p> <font size="2">Depressed mood*** 24.0 13.3 7.1 3.5<br>
</font> </p>

<p> <font size="2">Elated mood 31.1 35.4 4.1 3.9<br>
</font> </p>

<p> <font size="2">Panic 7.6 4.6 6.4 4.2<br>
</font> </p>

<p> <font size="2">Confusion** 34.4 27.5 10.4 5.6<br>
</font> </p>

<p> <font size="2">Distortion of</font> </p>

<p> <font size="2">perception 26.3 22.1 6.6 3.5<br>
</font> </p>

<p> <font size="2">Fantasizing 16.0 15.1 4.0 2.1<br>
</font> </p>

<p> <font size="2">----------------------------------------------------------------</font>
</p>

<p> <font size="2">· (5mg) - 285-285 n (7.5mg) - 404-413<br>
</font> </p>

<p> <font size="2">* P&lt;.05 ** P&lt;.Ol *** P&lt;.001<br>
</font> </p>

<p> <font size="2">However, in those patients reporting two or
more severe side effects isolated as separate groups, patients
receiving 5mg/m2 were more likely to continue on to a second THC
treatment, regardless of the number of severe side effects
reported. Forty-three percent of the patients who had experienced
two or more severe side effects continued on to a second THC
treatment when started at 5mg/m2. This compared with 29% of those
started at 7.5mg/m2. <br>
</font> </p>

<p> <u><font size="2">Discussion</font></u><font size="2">. This
first study included patients with a wide variety of cancer
types, covering a broad age range, and receiving treatment from
oncologists in community as well as university settings. It thus
served as a test of the antiemetic effect of THC under conditions
similar to those which would exist in clinical practice were the
drug generally available.<br>
</font> </p>

<p> <font size="2">Oral THC was found to be a safe and effective
antiemetic for most cancer chemotherapy patients. This study
shows that a single THC dose of 5mg/m2 causes fewer side effects
than 7.5mg/m2 while maintaining equal effectiveness. The larger
dose, 7.5mg/m2, should be considered for patients not deriving
sufficient protection from 5mg/m2<br>
</font> </p>

<p> <font size="2">The results of this study are particularly
noteworthy for two reasons:<br>
</font> </p>

<p> <font size="2">1) The large number of patients studied
strengthens conclusions reached regarding the effectiveness and
safety of THC. As of Cocchetto's 1981 review of the literature,
the largest sample size of the studies reported was only 116
patients. Ungerleider, et al., reported on 214 patients in 1982.
This Research Advisory Panel study, on the other hand, collected
detailed treatment reports and patient histories from 706
patients.<br>
</font> </p>

<p> <font size="2">2) Most of the patients enrolled in this
initial program had not responded to conventional antiemetics,
thus posing a more difficult therapeutic test than if THC had
been the first antiemetic drug used.<br>
<br>
The high drop-out rate and observations of individual patients
suggested that the rapid appearance of side effects in patients
with limited experience with disinhibiting drugs led to anxiety
and even panic. THC has an appreciable latent period, and, if the
drug is given immediately before chemotherapy a relatively large
single dose must be given to get a rapid effect. Such doses may
be effective but, when the effect is fully developed, will cause
more pronounced side effects. THC is known to have a long
half-life. Giving THC in a cumulative manner, that is, giving
repeated smaller doses at a longer time period prior to
chemotherapy, should allow more time for behavioral tolerance to
develop and achieve better patient acceptance but maintain
efficacy. To test that hypothesis a second trial was designed. <br>
</font> </p>

<p> <font size="2">Cumulative Dose Study<br>
<u>Summary</u>. The Cumulative Dose Protocol was designed to test
the above hypothesis, that the patient acceptance of oral THC
could be improved by using a cumulative dose schedule without the
lose of efficacy. The data below support that hypothesis. <br>
</font> </p>

<p> <u><font size="2">Patient and Investigator</font></u> </p>

<p> <u><font size="2">Demographics</font></u><font size="2">.
Patient demographics are similar to those of the first study and
are summarized for both protocols in Table K. Patients had a wide
variety of tumor types and received an assortment of
chemotherapeutic agents. In age, sex distribution, tumor types,
and anticancer treatment, the two cohorts did not differ
significantly. All patients had failed to achieve satisfactory
benefit from standard antiemetic before starting the study. The
most common antiemetic drug used prior to THC was
prochlorperazine.<br>
</font> </p>

<p> <u><font size="2">Study design</font></u><font size="2">.
Patients enrolled in the Cumulative Dose Protocol received 2.5mg
THC/m2 orally q4h, starting 4 doses prior to anticance treatment.
These patients were compared to a previous group of patients who
were treated under the standard protocol in which they received
5.Omg THC/m2 orally q4h, starting only 2 doses prior to
anticancer treatment. <br>
</font> </p>

<p> <font size="2">Results. The following is an analysis of the
results reported by California oncologists of their patients
enrolled in the Cumulative Dose Protocol. In this report, only
the first THC treatment was used in the comparative analysis of
the effectiveness and side effects to avoid bias due to over
representation of results from repeated trials on patients with
good response.<br>
</font> </p>

<p> <u><font size="2">Efficacy</font></u><font size="2">.
Physician ratings of nausea, vomiting and overall effectiveness
were similar in the initial and the cumulative protocols. Table L
compares the two cohorts as regards oncologists or nurses ratings
of nausea, vomiting and overall THC effectiveness. Although there
is a slight trend toward less nausea and less vomiting with
higher dose, with 952 confidence it is found that the
distribution of nausea and vomiting ratings are similar for both
protocols.' Similarly, 571 of patients rated THC as 'moderately'
or 'very' effective, exactly the same for the two dosage
schedules, indicating that side effects influence the overall
evaluation.<br>
</font> </p>

<p> <u><font size="2">Side Effects</font></u><font size="2">.
Table M summarizes the reports of moderate and severe THC side
effects and their severity as recorded by oncologists or nurses
on a standardized list. In no case was the percentage for a
moderate or severe side effect increased by the cumulative dosing
regimen; and the incidence of twelve of the thirteen side effects
listed was significantly reduced when compared to patients using
the initial THC protocol. <br>
</font> </p>

<p> <u><font size="2">THC Related Dropouts</font></u><font
size="2">. After the first treatment episode 27.5% of patients
receiving the cumulative dosing regimen and 22.9% of those
receiving the standard THC dosage dropped out of the trial. There
is no statistically significant difference in these dropout
rates.<br>
</font> </p>

<p> <u><font size="2">Conclusion</font></u><font size="2">. Based
on the preceding findings, it appears that prolonged exposure to
low dose THC is superior to standard THC therapy as an antiemetic
regimen for cancer chemotherapy patients. The cumulative dose
method decreases the number of moderate and severe side effects.
The cumulative dose method had no affect on the drug's reported
efficacy and had no affect on drop-out rate.<br>
</font> </p>

<p> <font size="2">Table K<br>
</font> </p>

<p> <font size="2">Patient Demographics</font> </p>

<p> <font size="2">--------------------<br>
Cumulative Dose Initial <br>
</font> </p>

<p> <font size="2">Protocol Protocol</font> </p>

<p> <font size="2">------------------ ---------------- <br>
</font> </p>

<p> <font size="2">(2.5mg THC/m2 with (5.Omg THC with<br>
</font> </p>

<p> <font size="2">4 loading doses) 2 loading doses)<br>
</font> </p>

<p> <font size="2">n - 134 n - 231<br>
<br>
</font> </p>

<p> <font size="2">Sex<br>
</font> </p>

<p> <font size="2">Males 38 % 46 %<br>
</font> </p>

<p> <font size="2">Females 62 % 54 %<br>
<br>
</font> </p>

<p> <font size="2">Age<br>
</font> </p>

<p> <font size="2">19 yrs or younger 7% 8%</font> </p>

<p> <font size="2">20 - 39 years 28% 34%</font> </p>

<p> <font size="2">40 - 59 years 44% 34%</font> </p>

<p> <font size="2">60 yrs or older 19% 23%<br>
</font> </p>

<p> <font size="2">--------------------------------------------------------------</font>
</p>

<p> <center><font size="2">Table L<br>
</font></center> </p>

<p> <font size="2">Comparison of Nausea, Vomiting and Overall
Effectiveness</font> </p>

<p> <font size="2">Between two THC Treatment Regimens<br>
</font> </p>

<p> <font size="2">--------------------------------------------------------
<br>
</font> </p>

<p> <font size="2">Ratings of Cumulative Single Dose</font> </p>

<p> <font size="2">---------- ---------- ----------- <br>
</font> </p>

<p> <font size="2">Nausea n - 124 n - 221<br>
</font> </p>

<p> <font size="2">None 17% 18%<br>
</font> </p>

<p> <font size="2">Mild 27% 32%<br>
</font> </p>

<p> <font size="2">Moderate 34% 31%<br>
</font> </p>

<p> <font size="2">Severe 22% 19%<br>
<br>
</font> </p>

<p> <font size="2">Vomiting n - 124 n - 221 <br>
</font> </p>

<p> <font size="2">None 32% 33%<br>
</font> </p>

<p> <font size="2">1 - 3 times 23% 29%<br>
</font> </p>

<p> <font size="2">3 - 4 times 14% 13%<br>
</font> </p>

<p> <font size="2">&gt; 4 times 31% 26%<br>
<br>
</font> </p>

<p> <font size="2">Overall Effectiveness n - 122 n - 221<br>
</font> </p>

<p> <font size="2">Not Effective 25% 20%<br>
</font> </p>

<p> <font size="2">Slightly 18% 23%<br>
</font> </p>

<p> <font size="2">Moderately 25% 25%<br>
</font> </p>

<p> <font size="2">Very 33% 32%<br>
</font> </p>

<p> <center><font size="2">Table M<br>
</font></center> </p>

<p> <font size="2">Comparison of the Incidence &amp; Severity of
Side Effects from THC</font> </p>

<p> <font size="2">Using Two Different Dosing Methods</font> </p>

<p> <font size="2">---------------------------------------------------------------
<br>
</font> </p>

<p> <font size="2">Side Effect Rated as Moderate Rated as Severe</font>
</p>

<p> <font size="2">(Incidence</font> </p>

<p> <font size="2">as Cumulative* Single Cumulative* Single</font>
</p>

<p> <font size="2">percentage) Dose** Dose**</font> </p>

<p> <font size="2">----------- ---------- ------ ----------
------<br>
</font> </p>

<p> <font size="2">Dry mouth** 19 40 3 6<br>
</font> </p>

<p> <font size="2">Tachycardia 2 5 0 1<br>
</font> </p>

<p> <font size="2">Ataxia** 2 15 2 1<br>
</font> </p>

<p> <font size="2">Dizziness 11 19 6 5<br>
</font> </p>

<p> <font size="2">Orthostatic</font> </p>

<p> <font size="2">hypotension 3 8 2 5<br>
</font> </p>

<p> <font size="2">Anxiety** 2 8 2 2<br>
</font> </p>

<p> <font size="2">Sedation* 19 46 9 9<br>
</font> </p>

<p> <font size="2">Elated mood 5 20 0 7<br>
</font> </p>

<p> <font size="2">Confusion** 8 24 2 5<br>
</font> </p>

<p> <font size="2">Distortion of</font> </p>

<p> <font size="2">perception 5 14 0 2<br>
</font> </p>

<p> <font size="2">Fantasizing 6 13 0 C<br>
</font> </p>

<p> <font size="2">Depressed mood 5 7 0 4<br>
</font> </p>

<p> <font size="2">Panic or fear 2 0 0 4<br>
</font> </p>

<p> <font size="2">-------------------------------------------------------------
<br>
</font> </p>

<p> <font size="2">* Cumulative N - 134 ** Single Dose N - 224<br>
</font> </p>

<p> <font size="2">Combination Protocol<br>
</font> </p>

<p> <u><font size="2">Summary</font></u><font size="2">. To
provide a more systematic and structured approach to the common
practice of combination antiemetic therapy, the Panel offered a
protocol for the optional use of THC alone or THC in combination
with prochlorperazine or other antiemetics. The Panel hoped that
required reporting of combinations of antiemetics used. would
provide additional information about efficacy and side effects of
various combinations. Under the Combination Protocol, the
majority of investigators either chose to use THC alone or THC in
combination with prochlorperazine. <br>
</font> </p>

<p> <font size="2">The results of the Combination Protocol study
support prior Cannabis Therapeutic Program studies in terms of
effectiveness and side effects. Only one clinically serious
adverse reaction was reported during the treatment of an
additional 657 patients with THC. Also, tabulation of the data
demonstrates no significant differences in reports of efficacy or
side effects between those cases where THC was used alone, cases
where THC was used in combination with prochlorperazine or other
antiemetics. Too few treatment reports alluded to combined use of
THC with other antiemetics to draw conclusions on the individual
combinations.<br>
</font> </p>

<p> <u><font size="2">Patient Demographics</font></u><font
size="2">. The Panel tabulated 2,263-reports of treatment
episodes on a total of 657 patients treated after January 1,
1984, the effective date for the combination protocol. These
numbers include treatment reports for 98 patients who were
administered marijuana cigarettes (including all prior protocols
which permitted use of smoked marijuana) and records for 70
patients who had received prior treatments with THC capsules
pursuant to protocols other than the Combination Protocol. There
were 489 patients who had not been previously treated with THC
under a prior protocol and who first received oral THC under the
Combination Protocol. A total of 1,674 discrete treatment
episodes were reported for these 489 patients. See Table N for a
description of patient characteristics. Table 0 tabulates the
emetogenicity ratings of the chemotherapy for the first treatment
episodes and Table P presents the distribution of types of tumors
treated. </font> </p>

<p> <u><font size="2">Study design</font></u><font size="2">. The
Panel had indications that some physicians were using other
antiemetics in combination with oral THC but not informing the
Panel or including such data on the treatment report forms. Aside
from THC as an antiemetic, it was clear that many oncologists
were now using poly<u>pharmacy</u> antiemetic therapy, with some
of the cocktails ranging up to 5 or 6 antiemetic drugs. The
combination protocol gave oncologists the option to start
patients either on THC alone or in combination with
prochlorperazine or dexamethasone. These combinations were
encouraged by the protocol but other combinations were permitted.<br>
</font> </p>

<p> <center><font size="2">Table N<br>
</font></center> </p>

<p> <center><font size="2">Patient Demographics</font></center> </p>

<p> <center><font size="2">-------------------- <br>
<br>
</font></center> </p>

<p> <font size="2">THC THC and Combination</font> </p>

<p> <font size="2">used other Protocol</font> </p>

<p> <font size="2">alone Antiemetics Totals <br>
</font> </p>

<p> <font size="2">n - 257 n - 232 n - 489<br>
</font> </p>

<p> <font size="2">No. % No. % No. %</font> </p>

<p> <font size="2">--- ----- --- ----- --- -----<br>
</font> </p>

<p> <font size="2">Sex<br>
</font> </p>

<p> <font size="2">Males 118 45.9 104 44.8 222 45.4<br>
</font> </p>

<p> <font size="2">Females 139 54.1 128 55.2 267 54.6<br>
<br>
</font> </p>

<p> <font size="2">Age 19 yrs or younger 31 12.1 31 13.4 62 12.7</font>
</p>

<p> <font size="2">20 - 39 yrs 74 28.8 101 43.5 175 35.8</font> </p>

<p> <font size="2">40 - 59 yrs 85 33.1 63 27.2 148 30.3</font> </p>

<p> <font size="2">60 yrs or more 67 26.1 37 15.9 104 21.3<br>
</font> </p>

<p> <font size="2">---------------------------------------------------------------------
<br>
<br>
<br>
</font> </p>

<p> <center><font size="2">Table 0<br>
</font></center> </p>

<p> <center><font size="2">Comparative Ratings of Emetogenicity<br>
</font></center> </p>

<p> <center><font size="2">of the Chemotherapy</font></center> </p>

<p> <center><font size="2">------------------------------------ <br>
<br>
</font></center> </p>

<p> <font size="2">THC THC and Combination</font> </p>

<p> <font size="2">used other Protocol</font> </p>

<p> <font size="2">alone Antiemetics Totals <br>
</font> </p>

<p> <font size="2">n - 257 n - 232 n - 489<br>
</font> </p>

<p> <font size="2">No. % No. % No. %</font> </p>

<p> <font size="2">----- --- -----<br>
</font> </p>

<p> <font size="2">Emetogenicity Rating<br>
</font> </p>

<p> <font size="2">Mild 17 6.7 13 5.6 30 6.1 <br>
</font> </p>

<p> <font size="2">Moderate 138 54.1 95 41.1 233 47.6<br>
</font> </p>

<p> <font size="2">Severe 61 23.9 85 36.8 146 29.9<br>
</font> </p>

<p> <font size="2">Radiation 22 8.6 25 10.8 47 9.6<br>
</font> </p>

<p> <font size="2">Unknown 19 8.5 14 6.0 33 6.7</font> </p>

<p> <font size="2">-----------------------------------------------------------------------
<br>
</font> </p>

<p> <center><font size="2">Table P<br>
</font></center> </p>

<p> <font size="2">Distribution of Tumor Types</font> </p>

<p> <font size="2">--------------------------- <br>
<br>
<br>
<br>
</font> </p>

<p> <font size="2">THC THC and Combination</font> </p>

<p> <font size="2">used other Protocol</font> </p>

<p> <font size="2">alone Antiemetics Totals <br>
</font> </p>

<p> <font size="2">n 257 n 232 n 489<br>
</font> </p>

<p> <font size="2">No. % No. % No. %</font> </p>

<p> <font size="2">--- ----- --- ----- --- -----<br>
</font> </p>

<p> <font size="2">Primary Tumor Site<br>
</font> </p>

<p> <font size="2">01 Hodgkins 24 9.3 44 19.0 68 13.9</font> </p>

<p> <font size="2">02 Other lymphomas 15 5.8 32 13.8 47 9.6</font>
</p>

<p> <font size="2">04 Lymphoid leukemia 7 2.7 6 2.6 13 2.7</font>
</p>

<p> <font size="2">05 Myeloid leukemia 3 1.2 2 0.9 5 1.0</font> </p>

<p> <font size="2">07 Other leukemia 2 0.8 2 0.4</font> </p>

<p> <font size="2">08 Leukemia unspec. 2 0.9 2 0.4</font> </p>

<p> <font size="2">09 Lymphosarcoma 5 1.9 5 2.2 10 2.0</font> </p>

<p> <font size="2">41 Tongue 2 0.9 2 0.4</font> </p>

<p> <font size="2">47 Nasopharynx 2 0.8 1 0.4 3 0.6</font> </p>

<p> <font size="2">49 Other oral cav. 1 0.4 1 0.2</font> </p>

<p> <font size="2">50 Esophagus 1 0.4 1 0.4 2 0.4</font> </p>

<p> <font size="2">51 Stomach 4 1.6 3 1.3 7 1.4</font> </p>

<p> <font size="2">53 Colon 11 4.3 1 0.4 12 2.5</font> </p>

<p> <font size="2">54 Rectum, rectosigmoid 2 0.8 1 0.4 3 0.6</font>
</p>

<p> <font size="2">55 Liver and intra 3 1.2 3 1.3 6 1.2</font> </p>

<p> <font size="2">56 Gallbladder ... 1 0.4 1 0.2</font> </p>

<p> <font size="2">57 Pancreas 3 1.2 5 2.2 8 1.6</font> </p>

<p> <font size="2">59 Other dig,torg. 3 1.2 3 0.6</font> </p>

<p> <font size="2">60 Nasal cavities ... 1 0.4 1 0.2</font> </p>

<p> <font size="2">62 Trachea, bronchi 40 15.6 18 7.8 58 11.9</font>
</p>

<p> <font size="2">64 Thymus, heart ... 2 0.8 8 3.4 10 2.0</font>
</p>

<p> <font size="2">70 Bone and articul 12 4.7 6 2.6 18 3.7</font>
</p>

<p> <font size="2">71 Connective, other 12 4.7 4 1.7 16 3.3</font>
</p>

<p> <font size="2">72 Melanoma of skin 3 1.2 2 0.9 5 1.0</font> </p>

<p> <font size="2">74 Female breast 58 22.6 41 17.7 99 20.2</font>
</p>

<p> <font size="2">79 Uterus ... 2 0.8 1 0.4 3 0.6</font> </p>

<p> <font size="2">80 Cervex, uteri ... 2 0.9 2 0.4</font> </p>

<p> <font size="2">83 Ovary... 24 9.3 19 8.2 43 8.8</font> </p>

<p> <font size="2">85 Prostate 3 1.2 1 0.4 4 0.8</font> </p>

<p> <font size="2">86 Testis 4 1.6 5 2.2 9 1.8</font> </p>

<p> <font size="2">88 Bladder 2 0.9 2 0.4</font> </p>

<p> <font size="2">89 Kidney and .... 2 0.8 2 0.9 4 0.8</font> </p>

<p> <font size="2">90 Eye 1 0.4 1 0.2</font> </p>

<p> <font size="2">91 Brain 2 0.8 5 2.2 7 1.4</font> </p>

<p> <font size="2">95 Other and ill-def 3 1.2 2 0.9 5 1.0</font> </p>

<p> <font size="2">96 Secondary... lymph 1 0.4 1 0.2</font> </p>

<p> <font size="2">99 Without spec. o 3 1.2 3 0.6</font> </p>

<p> <font size="2">Missing 3 1.3 3 0.6<br>
----------------------------------------------------------------------
<br>
</font> </p>

<p> <font size="2">Objectives of the study included: <br>
</font> </p>

<p> <font size="2">1. Does THC have a greater therapeutic effect
when used in combination with other standard antiemetics?<br>
</font> </p>

<p> <font size="2">2. Are THC/Compazine, THC/dexamethasone and
THC/Compazine/ dexamethasone combinations safe and free from
intolerable side effects?<br>
</font> </p>

<p> <font size="2">3. Which THC antiemetic combination is
preferred by cancer patients?<br>
</font> </p>

<p> <u><font size="2">Drug Dose and</font></u><font size="2">
Schedule. THC was to be given using the cumulative dose method.
Prochlorperazine, at a dose of 10mg orally, was to be
administered at the same time as the THC. Dexamethasone was to be
given 2 hours prior to chemotherapy as a single oral dose of
20mg. If a patient had not received a good response from the
THC/prochlorperazine or THC/dexamethasone combinations, in
subsequent treatment episodes the patient could be given THC,
plus both prochlorperazine and dexamethasone (at the dosage and
schedule outlined above.) <u>Results</u> from first treatment
episodes are emphasized because of the self-selection bias
expected in results from subsequent treatment episodes.<br>
</font> </p>

<p> <font size="2">Approximately one half of the treatment
reports indicated that the physician investigator chose to use
THC alone. Thus, in the tabulation of these reports &quot;THC
alone' serves as a 'control' for presentation of data for the
'THC used in combinations group. Little or no differences are
noted.<br>
</font> </p>

<p> <font size="2">The results of the Combination Protocol study
support prior Cannabis Therapeutic Program studies in terms of
effectiveness and side effects.<br>
</font> </p>

<p> <font size="2">Tabulation of data did not provide an answer
to the question of which THC antiemetic combination is preferred
by cancer patients. This is due in part to the small numbers of
reports on many of the antiemetic combinations. Also, in general,
the reports of efficacy and side effects are very similar
regardless of 'THC used alone' or 'THC used in all combinations'.
<br>
</font> </p>

<p> <font size="2">Tabulation of this data also did not
demonstrate any significant differences when results reported for
women were compared to results reported for men, nor for young
vs. old subjects. <br>
</font> </p>

<p> <u><font size="2">Efficacy</font></u><font size="2">. Table Q
provides a <u>summary</u> of nausea and vomiting ratings for the
first treatment episodes which were protected by THC alone, THC
combined with other antiemetics and as a total for the overall
experience with the 489 patients analyzed for this phase of the
Cannabis Therapeutic Program. Table R similarly summarizes the
overall effectiveness ratings.<br>
</font> </p>

<p> <u><font size="2">Side</font></u><font size="2"> Effects.
Overall, side effects do not constitute a major problem in the
therapeutic use of THC. This study not only confirms the first
study, but serious side effects ceased being reported as
physicians learned better how to use THC, lower doses, and
cumulative doses, and not on persons with brain damage. Table S
tabulates side effects reported for the first treatment episode
for patients treated with THC, treated with various combinations
of THC and other antiemetics, as well as the totals for the
Combination Protocol Study.<br>
</font> </p>

<p> <u><font size="2">Dropout</font></u><font size="2"> Rate.
Table T summarizes the reasons for dropping out from the study
after the first treatment episode.<br>
</font> </p>

<p> <u><font size="2">Discussion</font></u><font size="2">. The
only significant difference between this and the first THC study
is the use of combinations of antiemetics. Data on subjects
receiving polypharmacy have been compared with data on subjects
receiving THC alone. The similarities of results of the two
groups is remarkable. The only apparent difference is percent of
subjects willing to continue to additional treatment episodes
using combinations of antiemetics (70%) as opposed to those
treated with THC alone (46%).<br>
</font> </p>

<p> <font size="2">This study tended to confirm the findings of
the first study. An additional 657 patients were treated with THC
and their reports of impression of efficacy were similar to those
of the first study. Similar side effects were noted and only one
serious adverse reaction was reported. The lower dose, and to a
large extent, the cumulative dosing was being used.<br>
</font> </p>

<p> <u><font size="2">Additional information</font></u><font
size="2">. The popular polypharmacy does not appear to offer any
advantage in terms of effectiveness and little if any advantage
in terms of side effects. Again, no differences were found when
these data were analyzed by sex, or age.<br>
</font> </p>

<p> <center><font size="2">Table Q<br>
</font></center> </p>

<p> <center><font size="2">Comparative Ratings of Nausea and
Vomiting</font></center> </p>

<p> <center><font size="2">------------------------------------------
<br>
</font></center> </p>

<p> <font size="2">THC THC and Combination</font> </p>

<p> <font size="2">used other Protocol</font> </p>

<p> <font size="2">alone Antiemetics Totals <br>
</font> </p>

<p> <font size="2">n 257 n 232 n 489<br>
</font> </p>

<p> <font size="2">No. % No. % No. %</font> </p>

<p> <font size="2">----- --- ----- --- ----</font> </p>

<p> <font size="2">Nausea Rating<br>
</font> </p>

<p> <font size="2">None 38 15.1 50 21.7 88 18.0</font> </p>

<p> <font size="2">Mild 85 33.9 71 30.9 156 31.9</font> </p>

<p> <font size="2">Moderate 73 29.1 57 24.8 130 26.6</font> </p>

<p> <font size="2">Severe 55 21.9 52 22.6 107 21.9</font> </p>

<p> <font size="2">Missing 6 2 8 1.6<br>
<br>
</font> </p>

<p> <font size="2">Vomiting Rating<br>
</font> </p>

<p> <font size="2">None 89 35.3 70 30.4 159 32.5</font> </p>

<p> <font size="2">1 - 3 times 69 27.4 58 25.2 127 26.0</font> </p>

<p> <font size="2">4 - 6 times 35 13.9 40 17.4 75 15.3</font> </p>

<p> <font size="2">&gt; 6 times 59 23.4 62 27.0 121 24.7</font> </p>

<p> <font size="2">Missing 5 2 7 1.4<br>
</font> </p>

<p> <font size="2">----------------------------------------------------------------------
<br>
<br>
</font> </p>

<p> <center><font size="2">Table R<br>
</font></center> </p>

<p> <center><font size="2">Comparative Ratings of Overall
Effectiveness</font></center> </p>

<p> <center><font size="2">--------------------------------------------
<br>
</font></center> </p>

<p> <font size="2">THC THC and Combination</font> </p>

<p> <font size="2">used other Protocol</font> </p>

<p> <font size="2">alone Antiemetics Totals <br>
</font> </p>

<p> <font size="2">n - 257 n - 232 n - 489 <br>
</font> </p>

<p> <font size="2">No. % No. % No. %</font> </p>

<p> <font size="2">--- ----- --- ----- --- -----</font> </p>

<p> <font size="2">Overall Effectiveness<br>
</font> </p>

<p> <font size="2">Not effective 62 24.7 35 15.2 97 19.8</font> </p>

<p> <font size="2">Slightly 45 17.9 55 23.8 100 20.4</font> </p>

<p> <font size="2">Moderately 68 27.1 60 26.0 128 26.2</font> </p>

<p> <font size="2">Very 76 30.3 81 35.1 157 32.1</font> </p>

<p> <font size="2">Missing 6 1 7 1.4<br>
</font> </p>

<p> <font size="2">----------------------------------------------------------------------
<br>
</font> </p>

<p> <center><font size="2">Table S<br>
</font></center> </p>

<p> <center><font size="2">Comparative Ratings of Side Effects</font></center>
</p>

<p> <center><font size="2">----------------------------------- <br>
</font></center> </p>

<p> <font size="2">THC THC and Combination</font> </p>

<p> <font size="2">used other Protocol</font> </p>

<p> <font size="2">alone Antiemetics Totals <br>
</font> </p>

<p> <font size="2">n 257 n - 232 n 489<br>
</font> </p>

<p> <font size="2">No. % No. % No. %</font> </p>

<p> <font size="2">--- ----- --- ----- --- -----</font> </p>

<p> <font size="2">Incidence of</font> </p>

<p> <font size="2">Side Effects<br>
</font> </p>

<p> <font size="2">Dry mouth<br>
</font> </p>

<p> <font size="2">Severe 4 1.6 4 1.7 8 1.6</font> </p>

<p> <font size="2">Moderate 31 12.4 31 13.5 62 12.7</font> </p>

<p> <font size="2">Mild 77 30.8 57 24.8 134 27.4</font> </p>

<p> <font size="2">None 138 55.2 138 60 276 56.4</font> </p>

<p> <font size="2">Missing 7 2 9 1.8<br>
</font> </p>

<p> <font size="2">Tachycardia<br>
</font> </p>

<p> <font size="2">Severe 0 0.0</font> </p>

<p> <font size="2">Moderate 6 2.4 3 1.3 9 1.8</font> </p>

<p> <font size="2">Mild 19 7.6 14 6.1 33 6.7</font> </p>

<p> <font size="2">None 225 90 213 92.6 438 89.6</font> </p>

<p> <font size="2">Missing 7 2 9 1.8<br>
</font> </p>

<p> <font size="2">Ataxia<br>
</font> </p>

<p> <font size="2">Severe 1 0.4 1 0.2</font> </p>

<p> <font size="2">Moderate 4 1.6 7 3 11 2.2</font> </p>

<p> <font size="2">Mild 26 10.4 23 10 49 10.0</font> </p>

<p> <font size="2">None 219 87.6 200 87 419 85.7</font> </p>

<p> <font size="2">Missing 7 2 9 1.8<br>
</font> </p>

<p> <font size="2">Dizziness<br>
</font> </p>

<p> <font size="2">Severe 5 2 1 0.4 6 1.2</font> </p>

<p> <font size="2">Moderate 16 6.4 19 8.3 35 7.2</font> </p>

<p> <font size="2">Mild 46 18.4 50 21.7 96 19.6</font> </p>

<p> <font size="2">None 183 73.2 160 69.6 343 70.1</font> </p>

<p> <font size="2">Missing 7 2 9 1.8<br>
</font> </p>

<p> <font size="2">Orthostatic</font> </p>

<p> <font size="2">hypotension<br>
</font> </p>

<p> <font size="2">Severe 1 0.4 1 0.4 2 0.4</font> </p>

<p> <font size="2">Moderate 4 1.6 10 4.3 14 2.9</font> </p>

<p> <font size="2">Mild 27 10.8 31 13.5 58 11.9</font> </p>

<p> <font size="2">None 218 87.2 188 81.7 406 83.0</font> </p>

<p> <font size="2">Missing 7 2 9 1.8<br>
</font> </p>

<p> <font size="2">Anxiety<br>
</font> </p>

<p> <font size="2">Severe 7 2.8 1 0.4 8 1.6</font> </p>

<p> <font size="2">Moderate 8 3.2 15 6.6 23 4.7</font> </p>

<p> <font size="2">Mild 32 12.8 34 14.8 66 13.5</font> </p>

<p> <font size="2">None 203 81.2 179 78.2 382 78.1</font> </p>

<p> <font size="2">Missing 7 3 10 2.0<br>
</font> </p>

<p> <center><font size="1">Table S (Cont.)<br>
</font></center> </p>

<p> <font size="1">THC THC and Combination</font> </p>

<p> <font size="1">used other Protocol</font> </p>

<p> <font size="1">alone Antiemetics Totals <br>
</font> </p>

<p> <font size="1">No. % No. % No. %</font> </p>

<p> <font size="1">--- ----- --- ----- --- -----</font> </p>

<p> <font size="1">Sedation<br>
</font> </p>

<p> <font size="1">Severe 13 5.2 15 6.6 28 5.7</font> </p>

<p> <font size="1">Moderate 46 18.4 54 23.6 100 20.4</font> </p>

<p> <font size="1">Mild 101 40.4 74 32.3 175 35.8</font> </p>

<p> <font size="1">None 90 36 86 37.6 176 36.0</font> </p>

<p> <font size="1">Missing 7 3 10 2.0<br>
</font> </p>

<p> <font size="1">Elated mood<br>
</font> </p>

<p> <font size="1">Severe 6 2.4 8 3.5 14 2.9</font> </p>

<p> <font size="1">Moderate 22 8.8 20 8.7 42 8.6</font> </p>

<p> <font size="1">Mild 33 13.2 49 21.3 82 16.8</font> </p>

<p> <font size="1">None 189 75.6 153 66.5 342 69.9</font> </p>

<p> <font size="1">missing 7 2 9 1.8<br>
</font> </p>

<p> <font size="1">Confusion<br>
</font> </p>

<p> <font size="1">Severe 2 0.8 5 2.2 7 1.4</font> </p>

<p> <font size="1">Moderate 30 12 19 8.3 49 10.0</font> </p>

<p> <font size="1">Mild 47 18.8 65 28.4 112 22.9</font> </p>

<p> <font size="1">None 171 68.4 140 61.1 311 63.6</font> </p>

<p> <font size="1">Missing 7 3 10 2.0<br>
</font> </p>

<p> <font size="1">Distortion of</font> </p>

<p> <font size="1">perception<br>
</font> </p>

<p> <font size="1">Severe 2 0.8 1 0.4 3 0.6</font> </p>

<p> <font size="1">Moderate 12 4.8 13 5.7 25 5.1</font> </p>

<p> <font size="1">'Mild 43 17.2 32 13.9 75 15.3</font> </p>

<p> <font size="1">None 193 77.2 184 80 377 77.1</font> </p>

<p> <font size="1">Missing 7 2 9 1.8<br>
</font> </p>

<p> <font size="1">Fantasizing<br>
</font> </p>

<p> <font size="1">Severe 3 1.3 3 0.6</font> </p>

<p> <font size="1">Moderate 7 2.8 7 3 14 2.9</font> </p>

<p> <font size="1">Mild 22 8.8 15 6.5 37 7.6</font> </p>

<p> <font size="1">None 221 88.4 205 89.1 426 87.1</font> </p>

<p> <font size="1">Missing 7 2 9 1.8<br>
</font> </p>

<p> <font size="1">Depressed mood<br>
</font> </p>

<p> <font size="1">Severe 3 1.2 1 0.4 4 0.8</font> </p>

<p> <font size="1">Moderate 11 4.4 8 3.5 19 3.9</font> </p>

<p> <font size="1">Mild 19 7.6 18 7.9 37 7.6</font> </p>

<p> <font size="1">None 217 86.8 202 88.2 419 85.7</font> </p>

<p> <font size="1">Missing 7 3 10 2.0<br>
</font> </p>

<p> <font size="1">Panic or fear<br>
</font> </p>

<p> <font size="1">Severe 3 1.2 3 1.3 6 1.2</font> </p>

<p> <font size="1">Moderate 4 1.6 2 0.9 6 1.2</font> </p>

<p> <font size="1">Mild 12 4.8 13 5.7 25 5.1</font> </p>

<p> <font size="1">None. 231 92.4 212 92.2 443 90.6</font> </p>

<p> <font size="1">Missing 7 7 1.4<br>
</font> </p>

<p> <font size="1">-----------------------------------------------------------------------
<br>
</font> </p>

<p> <center><font size="2">Table T<br>
</font></center> </p>

<p> <center><font size="2">Comparison of Reasons for Termination</font></center>
</p>

<p> <center><font size="2">------------------------------------- <br>
<br>
</font></center> </p>

<p> <font size="2">THC THC and Combination</font> </p>

<p> <font size="2">used other Protocol</font> </p>

<p> <font size="2">alone Antiemetics Totals <br>
</font> </p>

<p> <font size="2">n 257 n - 232 n - 489<br>
</font> </p>

<p> <font size="2">No. % No. % No. %</font> </p>

<p> <font size="2">--- ----- --- ----- --- <br>
</font> </p>

<p> <font size="2">Reasons for</font> </p>

<p> <font size="2">Termination<br>
</font> </p>

<p> <font size="2">Ineffective as</font> </p>

<p> <font size="2">an antiemetic 40 15.6 20 8.6 60 12.3<br>
</font> </p>

<p> <font size="2">Side effects</font> </p>

<p> <font size="2">too severe 23 8.9 13 5.6 36 7.4<br>
</font> </p>

<p> <font size="2">Expired or</font> </p>

<p> <font size="2">completed treatment 69 26.8 26 11.2 95 19.4<br>
</font> </p>

<p> <font size="2">Other 6 2.3 11 4.7 17 3.5 <br>
</font> </p>

<p> <font size="2">Continued study 119 46.3 162 69.8 281 57.5<br>
<br>
</font> </p>

<hr>

<p> <a href="http://cliffcompaq/druglibrary/schaffer/index.htm">Cliff
Schaffer's Home Page</a> <br>
<br>
<br>
</p>
</body>
</html>
</DOC>